lobbying_filings_raw: 5b2c39e0-e357-4676-92f2-5abf75b5ab8b

Raw lobbying disclosure filings from the Senate Office of Public Records (SOPR). Each row is a single filing — registrations, quarterly reports, amendments, and terminations. Includes registrant and client names, reported income/expenses, filing period, and the full raw JSON from the API.

This data as json

filing_uuid filing_type registrant_id registrant_name client_id client_name filing_year filing_period received_date amount_reported is_amendment is_no_activity is_termination raw_json registrant_state registrant_country registrant_house_id client_state client_ppb_state client_country client_ppb_country client_general_description client_government_entity affiliated_org_count client_entity_id client_government_unit_id client_match_method client_match_confidence
5b2c39e0-e357-4676-92f2-5abf75b5ab8b Q1 305932 THE PETRIZZO GROUP, INC. 181799 SAGE THERAPEUTICS, INC. 2012 first_quarter 2012-04-16T11:29:03.333000-04:00 30000.0 0 0 0 {"url": "https://lda.senate.gov/api/v1/filings/5b2c39e0-e357-4676-92f2-5abf75b5ab8b/", "filing_uuid": "5b2c39e0-e357-4676-92f2-5abf75b5ab8b", "filing_type": "Q1", "filing_type_display": "1st Quarter - Report", "filing_year": 2012, "filing_period": "first_quarter", "filing_period_display": "1st Quarter (Jan 1 - Mar 31)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/5b2c39e0-e357-4676-92f2-5abf75b5ab8b/print/", "filing_document_content_type": "text/html", "income": "30000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Phillip J. Bond, President & CEO", "dt_posted": "2012-04-16T11:29:03.333000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1101 Pennsylvania Avenue, NW", "registrant_address_2": "Suite 654", "registrant_different_address": false, "registrant_city": "Washington", "registrant_state": "DC", "registrant_zip": "20004", "registrant": {"id": 305932, "url": "https://lda.senate.gov/api/v1/registrants/305932/", "house_registrant_id": 38088, "name": "THE PETRIZZO GROUP, INC.", "description": "Government Relations and Strategic Communications Firm", "address_1": "601 New Jersey Avenue NW", "address_2": "Suite 830", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20001", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "T.J. PETRIZZO", "contact_telephone": "+1 202-365-4583", "dt_updated": "2026-01-10T16:22:46.380302-05:00"}, "client": {"id": 181799, "url": "https://lda.senate.gov/api/v1/clients/181799/", "client_id": 1004948, "name": "SAGE THERAPEUTICS, INC.", "general_description": "Neuropsychiatric therapeutics company", "client_government_entity": false, "client_self_select": false, "state": "MA", "state_display": "Massachusetts", "country": "US", "country_display": "United States of America", "ppb_state": "MA", "ppb_state_display": "Massachusetts", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2011-02-01"}, "lobbying_activities": [{"general_issue_code": "DEF", "general_issue_code_display": "Defense", "description": "Letter of Support for Innovation Grant Application", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 3241, "prefix": null, "prefix_display": null, "first_name": "TJ", "nickname": null, "middle_name": null, "last_name": "PETRIZZO", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 58063, "prefix": "mr", "prefix_display": "MR.", "first_name": "PHILLIP", "nickname": null, "middle_name": "J", "last_name": "BOND", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 25, "name": "Defense, Dept of (DOD)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "MED", "general_issue_code_display": "Medical/Disease Research/Clinical Labs", "description": "Letter of Support for Innovation Grant Application", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 3241, "prefix": null, "prefix_display": null, "first_name": "TJ", "nickname": null, "middle_name": null, "last_name": "PETRIZZO", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 58063, "prefix": "mr", "prefix_display": "MR.", "first_name": "PHILLIP", "nickname": null, "middle_name": "J", "last_name": "BOND", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 25, "name": "Defense, Dept of (DOD)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} DC US 38088 MA MA US US Neuropsychiatric therapeutics company 0 0 2063078   normalized_name 0.7

Links from other tables